Related Experiment Video
Updated: Jul 25, 2026
08:53
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Prognostic factors in Hodgkin's disease
Mariano Provencio1, Pilar España, Isabel Millán
1Medical Oncology Service, "Puerta de Hierro" University Hospital, Autonomous University of Madrid, Spain. mprovenciop@seom.org
Leukemia & Lymphoma
|September 14, 2004
Summary
This study identified key prognostic factors for Hodgkin's disease (HD) relapse, including male gender and advanced stages. Findings aid in tailoring treatments for improved patient outcomes and survival rates.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Hodgkin's disease (HD) is a curable malignancy.
- Patient relapse occurs in some cases, necessitating identification of prognostic factors.
- Adapting treatments based on individual risk is crucial for improving outcomes.
Purpose of the Study:
- To analyze prognostic factors influencing disease-free and overall survival in Hodgkin's disease patients.
- To identify risk factors for relapse and guide treatment optimization.
Main Methods:
- Retrospective analysis of 526 Hodgkin's disease patients diagnosed between 1967 and 2001.
- Evaluation of demographic, clinical, and treatment-related variables.
- Statistical analysis of overall and disease-free survival rates.
Main Results:
- Overall survival rates at 2, 5, 10, and 15 years were 94%, 86%, 76%, and 72%, respectively.
- Poor prognostic factors for overall survival included male gender, lymphocyte depletion, advanced stages (III-IV), B symptoms, spleen involvement, lack of complete remission, and age >30.
- Risk factors for disease-free survival included male gender, lymphocyte depletion, advanced stages (III-IV), B symptoms, extranodal/splenic involvement, and lack of complete remission.
Conclusions:
- Several factors significantly impact Hodgkin's disease prognosis and survival.
- Identification of these risk factors allows for patient stratification.
- Treatment optimization based on identified risk groups can lead to improved outcomes and differentiated therapeutic strategies.
